A novel CRTH2 antagonist: Single- and multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ACT-453859 in healthy subjects

Journal of Clinical Pharmacology

Volumn 55, Issue 7, 2015, Pages 787-797

  Géhin, Martine ^a   Strasser, Daniel S ^a   Zisowsky, Jochen ^a   Farine, Hervé ^a   Groenen, Peter M A ^a   Dingemanse, Jasper ^a   Sidharta, Patricia N ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

ACT 453859; CRTH2; entry into humans study; pharmacokinetics; receptor internalization

Indexed keywords

ACETIC ACID DERIVATIVE; ACT 453859; CHEMOATTRACTANT RECEPTOR HOMOLOGOUS MOLECULE EXPRESSED ON T HELPER 2 ANTAGONIST; PLACEBO; SETIPIPRANT; UNCLASSIFIED DRUG; ACT-453859; CARBAZOLE DERIVATIVE; IMMUNOGLOBULIN RECEPTOR; PROSTAGLANDIN D2 RECEPTOR; PROSTAGLANDIN RECEPTOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CONCENTRATION (PARAMETERS); CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; ELIMINATION HALF-LIFE; EOSINOPHIL; FEMALE; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION; ADOLESCENT; ANTAGONISTS AND INHIBITORS; HALF LIFE TIME; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ACETATES; ADOLESCENT; ADULT; CARBAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EOSINOPHILS; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; YOUNG ADULT;

EID: 84930654682     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.478     Document Type: Article

References (26)

1. Nagata K, Hirai H, Tanaka K, et al., CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Lett. 1999; 459 (2): 195-199.
2. Pettipher R., The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses. Br J Pharmacol. 2008; 153 (suppl 1): S191-S199.
3. Murray JJ, Tonnel AB, Brash AR, et al., Release of prostaglandin D2 into human airways during acute antigen challenge. N Engl J Med. 1986; 315 (13): 800-804.
4. Robinson DS., Th-2 cytokines in allergic disease. Br Med Bull. 2000; 56 (4): 956-968.
5. Tanaka K, Hirai H, Takano S, Nakamura M, Nagata K., Effects of prostaglandin D2 on helper T cell functions. Biochem Biophys Res Commun. 2004; 316 (4): 1009-1014.
6. Xue L, Gyles SL, Wettey FR, et al., Prostaglandin D2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells. J Immunol. 2005; 175 (10): 6531-6536.
7. Gervais FG, Cruz RP, Chateauneuf A, et al., Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP. J Allergy Clin Immunol. 2001; 108 (6): 982-988.
8. Kostenis E, Ulven T., Emerging roles of DP and CRTH2 in allergic inflammation. Trends Mol Med. 2006; 12 (4): 148-158.
9. Philip G, van Adelsberg J, Loeys T, et al., Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis. J Allergy Clin Immunol. 2009; 124 (5): 942-948, e941-e949.
10. Shiraishi Y, Takeda K, Domenico J, Gelfand EW., Role of prostaglandin D2 and CRTH2 blockade in early- and late-phase nasal responses. Clin Exp Allergy. 2014; 44 (8): 1076-1082.
11. Brozek JL, Bousquet J, Baena-Cagnani CE, et al., Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010; 126 (3): 466-476.
12. Arima M, Fukuda T., Prostaglandin D2 receptors DP and CRTH2 in the pathogenesis of asthma. Curr Mol Med. 2008; 8 (5): 365-375.
13. Apter AJ., Advances in adult asthma diagnosis and treatment in 2013. J Allergy Clin Immunol. 2014; 133 (1): 49-56.
14. Straumann A, Hoesli S, Bussmann C, et al., Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy. 2013; 68 (3): 375-385.
15. Brandt EB, Sivaprasad U., Th2 Cytokines and Atopic Dermatitis. J Clin Cell Immunol. 2011; 2 (3): pii, 110.
16. Charlesworth EN, Kagey-Sobotka A, Schleimer RP, Norman PS, Lichtenstein LM., Prednisone inhibits the appearance of inflammatory mediators and the influx of eosinophils and basophils associated with the cutaneous late-phase response to allergen. J Immunol. 1991; 146 (2): 671-676.
17. Sidharta PN, Diamant Z, Dingemanse J., Single- and multiple-dose tolerability and pharmacokinetics of the CRTH2 antagonist setipiprant in healthy male subjects. Fundam Clin Pharmacol. 2014; 28 (6): 690-699.
18. Diamant Z, Sidharta PN, Singh D, et al., Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy. 2014; 44 (8): 1044-1052.
19. FDA. Guidance for Industry: Food-effect bioavailability and fed bioequivalence studies; December 2002.
20. Baldoni D, Mackie A, Gutierrez M, Theodor R, Dingemanse J., Setipiprant, a selective oral antagonist of human CRTH2: relative bioavailability of a capsule and a tablet formulation in healthy female and male subjects. Clin Ther. 2013; 35 (11): 1842-1848.
21. Maganti L, Panebianco DL, Maes AL., Evaluation of methods for estimating time to steady state with examples from phase 1 studies. AAPS J. 2008; 10 (1): 141-147.
22. Gough K, Hutchison M, Keene O, et al., Assessment of dose proportionality: Report from the statisticians in The Pharmaceutical Industry/Pharmacokinetics UK joint working party. Drug Inf J. 1995; 29: 1039-1048.
23. Bain G, King CD, Brittain J, et al., Pharmacodynamics, pharmacokinetics, and safety of A M211: a novel and potent antagonist of the prostaglandin D2 receptor type 2. J Clin Pharmacol. 2012; 52 (10): 1482-1493.
24. Horak F, Zieglmayer P, Zieglmayer R, et al., The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial. Allergy. 2012; 67 (12): 1572-1579.
25. Barnes N, Pavord I, Chuchalin A, et al., A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy. 2012; 42 (1): 38-48.
26. Singh D, Cadden P, Hunter M, et al., Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459. Eur Respir J. 2013; 41 (1): 46-52.